Analytical Data
-
基因名
USP27X
- Application
-
别名
USP22L; USP27
-
种属
Human
-
表达系统
Baculovirus
-
标签
His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
A6NNY8
-
表达区间
C2-Y438
-
蛋白长度
Full Length
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
USP27X is a deubiquitinating enzyme that has garnered attention in recent years due to its roles in various cellular processes, including protein stability, cell signaling, and the regulation of gene expression. The research surrounding USP27X is primarily motivated by its implications in cancer biology and other diseases associated with dysregulated protein ubiquitination. Ubiquitination is a crucial post-translational modification that can tag proteins for degradation or alter their function and activity. Investigations have revealed that USP27X can stabilize specific target proteins by removing ubiquitin molecules, thereby preventing their degradation. This mechanism is particularly significant in cancer, where the aberrant expression of USP27X has been linked to tumor progression and poor patient prognosis. Furthermore, USP27X has shown potential interactions with key oncogenic pathways, making it a candidate for therapeutic targeting. Understanding the precise molecular mechanisms of USP27X and its interactions could provide valuable insights into developing novel cancer therapies and contribute to a broader comprehension of ubiquitin-mediated regulation in health and disease. As research progresses, USP27X may emerge as a crucial player in the ubiquitin-proteasome system, influencing not only cancer biology but also various physiological processes.












